Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05154578 |
Recruitment Status :
Completed
First Posted : December 13, 2021
Last Update Posted : March 28, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Group B Streptococcal Infection | Biological: GBS-NN/NN2 Vaccine Biological: Placebo | Phase 2 |
This is a phase II, multicentre, multinational, randomized, parallel group, placebo-controlled study of four vaccination regimens in healthy pregnant women. There will be 5 treatment groups; Group 1 will receive one injection of placebo at 22 (±1) weeks gestational age (GA), one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA. Group 2 will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of placebo at 30 (±1) weeks GA.Group 3 will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of placebo at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA. Group 4 will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of placebo at 30 (±1) weeks GA.
Group 5 will receive an injection of placebo at 22, 26 and 30 weeks (±1) GA. Participants will attend the clinic for assessment visits up to delivery and for a further 3 visits at 28 (±4) days, 90 (±6) days and 180 (±14) days post delivery.
Babies will be also be assessed at delivery, and 28 (±4) days, 90 (±6) days and 180 (±14) days post delivery.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 272 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Participants will be randomized to one of 5 groups |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | A Multicentre, Multinational, Parallel Group, Observer-blind, Randomised, Placebo-controlled Study on the Group B Streptococcus Vaccine (GBS-NN/NN2), Investigating the Immunogenicity and Safety of Four Vaccination Regimens in Pregnant Woman, Assessing IgG Specific to AlpN Proteins in Cord Blood and Maternal Blood, and the Safety Profile in Mother and Infant up to 6 Months Post-delivery |
Actual Study Start Date : | February 17, 2022 |
Actual Primary Completion Date : | April 26, 2023 |
Actual Study Completion Date : | October 18, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Group 1: 4 week dose interval; 2 doses
Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
|
Biological: GBS-NN/NN2 Vaccine
0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection. Biological: Placebo 0.5 mL normal saline given by intramuscular injection
Other Name: Normal saline |
Experimental: Group 2: early intervention; 4 week dose interval; 2 doses
Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of placebo at 30 (±1) weeks GA
|
Biological: GBS-NN/NN2 Vaccine
0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection. Biological: Placebo 0.5 mL normal saline given by intramuscular injection
Other Name: Normal saline |
Experimental: Group 3: early intervention; 8 week dose interval; 2 doses
Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of placebo at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
|
Biological: GBS-NN/NN2 Vaccine
0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection. Biological: Placebo 0.5 mL normal saline given by intramuscular injection
Other Name: Normal saline |
Experimental: Group 4: single dose
Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA, and one injection of placebo at 30 (±1) weeks GA.
|
Biological: GBS-NN/NN2 Vaccine
0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection. Biological: Placebo 0.5 mL normal saline given by intramuscular injection
Other Name: Normal saline |
Placebo Comparator: Group 5: placebo
Participants will receive one injection of placebo at 22, 26 and 30 weeks (±1) GA
|
Biological: Placebo
0.5 mL normal saline given by intramuscular injection
Other Name: Normal saline |
- Concentrations of Immunoglobulin (Ig) G antibodies specific to the AlpN proteins in μg/mL in cord blood from each baby [ Time Frame: Delivery ]Concentrations of IgG antibodies specific to the AlpN proteins in μg/mL in cord blood from each baby
- Injection site reactions in the mother [ Time Frame: To Day 84 ]Number of participants with solicited injection site reactions following vaccination
- Adverse events following the vaccinations in the mother [ Time Frame: To Day 84 ]Number of participants with solicited and other adverse events following the vaccinations
- Clinically significant abnormal laboratory tests in the mother [ Time Frame: To Day 84 ]Number of participants with clinically significant abnormal laboratory tests in the mother
- Clinically significant changes in vital signs in the mother [ Time Frame: To Day 84 ]Number of participants with clinically significant changes in vital signs (heart rate,blood pressure, oral temperature) in the mother
- Clinically significant changes in physical examination in the mother [ Time Frame: To Day 84 ]Number of participants with clinically significant changes in physical examination in the mother
- Gestational weight in the baby [ Time Frame: Delivery, 28 days, 90 days and 180 days post delivery. ]Gestational weight in the baby
- Weight in the baby [ Time Frame: Delivery, 28 days, 90 days and 180 days post delivery. ]Weight in the baby
- Length in the baby [ Time Frame: Delivery, 28 days, 90 days and 180 days post delivery. ]Length in the baby
- Head circumference in the baby [ Time Frame: Delivery, 28 days, 90 days and 180 days post delivery. ]Head circumference in the baby
- Apgar score in the baby [ Time Frame: 1, 5 and 10 minutes ]Apgar score in the baby, range 0 to 10 where high scores are good and low scores are bad
- Developmental milestones in the baby using Ages & Stages questionnaire [ Time Frame: 6 months ]Developmental milestones in the baby using Ages & Stages questionnaire
- Concentrations of IgG antibodies specific to the AlpN proteins in μg/mL in maternal blood [ Time Frame: Delivery ]Concentrations of IgG antibodies specific to the AlpN proteins in μg/mL in maternal blood
- Concentrations of IgG antibodies specific to the AlpN proteins in μg/mL in blood from each baby [ Time Frame: 1 month, 3 months ]Concentrations of IgG antibodies specific to the AlpN proteins in μg/mL in blood from each baby
- Opsonophagocytic killing assay (OPKA) titres [ Time Frame: Delivery ]OPKA titres in cord blood and maternal blood
- Concentrations of IgG antibodies specific to the NN and NN2 fusion proteins in maternal blood [ Time Frame: 4 weeks after each dose; at delivery ]Concentrations of IgG antibodies specific to the NN and NN2 fusion proteins in maternal blood
- Concentrations of IgG and IgA antibodies specific to the AlpN proteins in colostrum and in breast milk [ Time Frame: Within 48 hours of delivery; 1 month and 3 months post-delivery ]Concentrations of IgG and IgA antibodies specific to the AlpN proteins in colostrum and in breast milk
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy pregnant woman above the legally defined age of consent at the time of screening
- Carrying a normal singleton pregnancy, and is at 21+0 to 23+6 weeks GA at the planned tme of the 1st vaccination, as established by first/second trimester ultrasound examination
- Properly informed about the study and has given written informed consent and parental consent (for her baby) in accordance with the International Conference on Harmonization Good Clinical Practice (ICH GCP) and local legislation prior to the first study intervention
- Grants access to her own and her baby's study related medical records
Exclusion Criteria
- Previous vaccination with an investigational Group B Streptococcus (GBS) Vaccine
- BMI of <17 or >40 at the time of screening
- Human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) positive or positive for syphilis
- Knowingly carrying, at screening, a malformed or genetically abnormal foetus, incl. renal pelvis dilation, single umbilical artery (screening will be undertaken after the ultrasound conducted for the detection of anomalies)
- Chronic or pregnancy induced hypertension at screening, >1+ protein in urine regardless of blood pressure or 1+ protein in urine and hypertension
- Experienced a previous stillbirth prior to going into labour
- Gestational, type 1 or type 2 diabetes
- Potential placenta previa as per malformation ultrasound scan
- Rhesus negative and has anti-D antibodies or other potential harmful antibodies
- Known or suspected allergies to any components of the vaccine including to aluminium or aminoglycoside antibiotics, or an allergic reaction related to a previous vaccination
- Fever (temperature >37.9°C) on the day of receiving the first dose or an acute infection in the 7 days before the first dose (the first dose can be delayed if gestational age permits)
- Received systemic steroids in the 6 weeks before the first dose (inhaled and topical steroids are acceptable)
- Any lesion (including tattoos) at the planned injection site that will impair the assessment of the injection site
- Received immunosuppressive medication, chemotherapy or radiotherapy in the 24 weeks before the first dose
- Received blood, blood products, plasma derivatives or any immunoglobulin preparations in the 12 weeks before the first dose
- Anaemia, haemoglobin (<10 g/dL, 100 g/L, 6.2 mmol/L)
- Currently breast feeding
- Received any investigational medicinal product or vaccine in the 12 weeks or 5 half-lives before the first dose
- Received an approved vaccine within the 4 weeks before the first dose or expects to receive an approved vaccine during the study. Routine vaccinations recommended during pregnancy (e.g., pertussis and influenza) are permitted but every effort should be made to separate routine vaccinations from the trial vaccinations by at least 7 days.
- Known or suspected immunodeficiency or cancer (leukaemia, lymphoma), or a family history of congenital or hereditary immunodeficiency
- History or presence of uncontrolled cardiovascular disease, pulmonary, hepatic, gall bladder or biliary tract, renal, haematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, psychiatric, or autoimmune disease
- History of, or current drug or alcohol abuse
- In the opinion of the investigator not suitable for inclusion in the study
- The pregnancy is considered high risk by treating physicians
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05154578
Denmark | |
Aarhus University Hospital; Skejby | |
Aarhus, Denmark | |
Hvidovre University Hospital | |
Hvidovre, Denmark | |
Institut for Regional Sundhedsforskning | |
Kolding, Denmark | |
South Africa | |
ESRU Rahima Moosa Mother and Child Hospital | |
Johannesburg, South Africa | |
Shandukani Research Clinic | |
Johannesburg, South Africa | |
Wits Vaccines & Infectious Diseases Analytics | |
Johannesburg, South Africa | |
Mecru Clinical Research Unit (MeCRU) | |
Pretoria, South Africa | |
Setshaba Research Centre | |
Pretoria, South Africa | |
United Kingdom | |
St George's University Hospital | |
London, United Kingdom | |
University Hospital Southampton | |
Southampton, United Kingdom |
Study Director: | Geoff Kitson | gkitson@propharmapartners.uk.com |
Responsible Party: | Minervax ApS |
ClinicalTrials.gov Identifier: | NCT05154578 |
Other Study ID Numbers: |
MVX0004 |
First Posted: | December 13, 2021 Key Record Dates |
Last Update Posted: | March 28, 2024 |
Last Verified: | March 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Streptococcal Infections Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Infections |